Correction to: Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

被引：0
|
作者：
Taylor M. Patek
Chengwen Teng
Kaitlin E. Kennedy
Carlos A. Alvarez
Christopher R. Frei
机构：
[1] The University of Texas at Austin,Pharmacotherapy Division, College of Pharmacy
[2] The University of Texas Health Science Center at San Antonio,Pharmacotherapy Education and Research Center, Long School of Medicine
[3] Texas Tech University Health Sciences Center,Division of Clinical/Translational Research, Hodge School of Pharmacy
[4] South Texas Veterans Health Care System,undefined
[5] University Health System,undefined
来源：
Drug Safety | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In the original publication of the article, the second sentence in the figure 2 caption should read as below:
引用
下载
收藏
页码：825 / 825
相关论文
共 50 条
  • [31] Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
    Luyu Liu
    Shaobo Wu
    Liangliang Wei
    Zhihao Xia
    Jiajia Ji
    Dageng Huang
    Aging Clinical and Experimental Research, 37 (1)
  • [32] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Zhang, Meilian
    Xie, Wenhuo
    Li, Jianbin
    Zheng, Jiaping
    Zhou, Yu
    ARCHIVES OF WOMENS MENTAL HEALTH, 2023, 27 (1) : 35 - 44
  • [33] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Meilian Zhang
    Wenhuo Xie
    Jianbin Li
    Jiaping Zheng
    Yu Zhou
    Archives of Women's Mental Health, 2024, 27 : 35 - 44
  • [34] Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
    Bao, Yiwen
    Chen, Jiaju
    Duan, Luting
    Wang, Fujue
    Lai, Han
    Mo, Zeming
    Zhu, Weiliang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Ximu Sun
    Han Zhou
    Yanming Li
    Yanhui Luo
    Qixiang Guo
    Yixin Sun
    Chenguang Jia
    Bin Wang
    Maoquan Qin
    Peng Guo
    Future Journal of Pharmaceutical Sciences, 11 (1)
  • [36] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [37] Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
    Yidan Li
    Shengzhu Sun
    Hongyun Wu
    Leiyong Zhao
    Wei Peng
    BMC Pharmacology and Toxicology, 25 (1)
  • [38] Postmarketing Safety of Irinotecan and Association with Pharmacogenomic Studies: a Pharmacovigilance Study Based on FDA Adverse Event Reporting System (FAERS)
    Kong, Lingti
    Rong, Li
    Qiu, Hongyu
    Xie, Mengyuan
    Xu, Jian
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1632 - 1638
  • [39] Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
    Yifan Hong
    Kebin Cheng
    Han Qu
    Yuting Wang
    Yuanyuan Wang
    Guorong Fan
    Zhenghua Wu
    Journal of Pharmaceutical Health Care and Sciences, 10 (1)
  • [40] A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
    Cui, Zhiwei
    Cheng, Feiyan
    Wang, Lihui
    Zou, Fan
    Pan, Rumeng
    Tian, Yuhan
    Zhang, Xiyuan
    She, Jing
    Zhang, Yidan
    Yang, Xinyuan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345